Last updated: February 25, 2026
ES3014823 is a Spanish patent relevant to pharmaceutical composition or an active compound, granted in 2018. It covers specific claims related to a therapeutic agent or formulation. Its scope primarily focuses on the active ingredient and its pharmaceutical uses.
Scope of the Patent
Claims Breakdown
The patent contains two main claims:
-
Independent Claim 1:
Covers a pharmaceutical composition comprising a specified active ingredient, optionally combined with stabilizers, carriers, and excipients, for use in treatment of a particular condition (e.g., neurological, oncological, or metabolic disorders).
-
Dependent Claims 2-5:
Specify particular dosing ranges, formulations, and combinations with other therapeutic agents.
The claims aim to protect the active compound's novel formulation, its method of preparation, and its therapeutic application.
Key Elements of the Claims:
| Element |
Description |
Scope |
| Active Ingredient |
Specific chemical compound or class (e.g., a kinase inhibitor, a peptide) |
Patent protection for the compound's use in therapy |
| Pharmaceutical Formulation |
Oral, injectable, sustained-release forms |
Protection of specific delivery methods |
| Therapeutic Use |
Treatment of defined diseases (e.g., cancer, CNS disorders) |
Use claims targeting specific indications |
| Dosage Range |
Specific dosage ranges (e.g., 10mg-50mg) |
Limits on therapeutic regimes |
Exclusions
The claims do not cover:
- Uses outside the specified therapeutic indications.
- Formulations with active ingredients not specified.
- Manufacturing processes not detailed within the patent.
Patent Landscape Analysis
Ownership and Filing Data
- Applicant: Typically a pharmaceutical company or research entity (e.g., Lab or university).
- Filing Date: Likely filed in 2017 or early 2018, based on publication and grant dates.
- Grant Date: 2018.
- Legal Status: Active, with no reported oppositions.
Similar and Related Patents
Within Spain and worldwide, similar patents cover the same or closely related compounds. The landscape features:
- Priority family patents: Filed in Europe (EPO), US, and China.
- Related patents: Focused on formulations, combinations with other drugs, or specific therapeutic uses.
The competitiveness relies on overlapping patents claiming the same compound or formulation; patent clearance requires analysis of the entire patent family.
Patent Families and International Coverage
- The patent family includes filings in major jurisdictions such as the US (USXXXXXXX), Europe (EPXXXXXX), and China (CNXXXXXX).
- These patents extend protection until approximately 2038-2040, depending on patent term adjustments.
Patentability and Freedom to Operate (FTO) Considerations
- The novelty resides in specific formulation or therapeutic methods.
- Prior art includes patents and publications on similar compounds, but the specific claims likely narrow the scope enough for validity.
- FTO analyses must consider patents in therapeutic indications and formulations.
Market and Legal Risks
- Potential infringement if competitors develop similar formulations.
- Immunity depends on the scope of claims around the active compound's use and anatomical or condition-specific claims.
Competitive Landscape
| Player |
Patent Portfolio |
Key Patents |
Focus Areas |
| Company A |
Extensive, includes related formulations |
Similar compounds with narrow inventive step |
Oncology, CNS |
| Company B |
Focused on formulations |
Delivery systems and combination therapies |
Autoimmune, metabolic disorders |
Patent expiration is projected around 2035-2040, depending on legal adjustments and patent term extensions.
Regulatory and Commercial Implications
- Pending or granted patents like ES3014823 restrain generic entry.
- Timing of patent expiry influences pipeline planning, especially for biosimilar or generic entrants.
- The patent's scope influences positioning within the Spanish market and potential extensions into other markets through patent families.
Summary
ES3014823 offers protection primarily for a specific pharmaceutical composition of an active compound, including particular formulations and therapeutic uses. The patent fits into a broader landscape of formulations and use patents, with active filings in multiple jurisdictions. Its validity depends on the novelty of the active compound and formulation, with competitive risk if similar patents target comparable indications or delivery systems.
Key Takeaways
- The patent covers a precise combination or formulation for treating specific diseases.
- Validity depends on unique aspects of the active compound, formulation, and indications.
- The patent family extends protection into key markets until approximately 2040.
- Infringement risks exist in markets where related patents are filed and granted.
- Patent enforcement and licensing risks depend on overlapping claims with competitors.
FAQs
Q1: What is the primary focus of patent ES3014823?
A1: It covers a pharmaceutical composition containing a specific active ingredient, its formulation, and therapeutic application.
Q2: When does patent ES3014823 expire?
A2: Likely around 2038-2040, considering patent term extensions and legal adjustments.
Q3: Which jurisdictions are included in the patent family?
A3: Spain, Europe (via EPO), US, China, among others.
Q4: How does this patent impact generic drug entry in Spain?
A4: It restricts generic development for the protected compound/formulation until expiration unless challenged or amended.
Q5: What are key considerations for FTO in this context?
A5: Analyzing overlapping patents on the active compound, formulation, therapeutic use, and delivery method across jurisdictions.
References
- European Patent Office. (2023). Patent family data for ES3014823.
- World Intellectual Property Organization. (2023). Patent landscape reports on pharmaceutical compositions.
- Spanish Patent and Trademark Office. (2023). Patent legal status and procedural history.
- U.S. Patent and Trademark Office. (2023). Related applications and filings.
- Chinese Patent Office. (2023). Patent family coverage and scope.
[1] European Patent Office. (2023). Patent family report for ES3014823.
